Biofrontera (BFRI) has released an update to notify the public and investors about an entry into a material definitive agreement.
Biofrontera Inc. amended its License and Supply Agreement, altering the payment schedule and deferring a payment originally due on January 31, 2024, to February 29, 2024. This amendment affects financial obligations between Biofrontera Inc., Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH, and their parent company, Biofrontera AG, regarding purchases of Licensed Products.
For further insights into BFRI stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
